UA95099C2 - Применение деферипрона при лечении железо-индуцированного повреждения митохондрий, который является следствием атаксии фридрейха - Google Patents

Применение деферипрона при лечении железо-индуцированного повреждения митохондрий, который является следствием атаксии фридрейха

Info

Publication number
UA95099C2
UA95099C2 UAA200810608A UAA200810608A UA95099C2 UA 95099 C2 UA95099 C2 UA 95099C2 UA A200810608 A UAA200810608 A UA A200810608A UA A200810608 A UAA200810608 A UA A200810608A UA 95099 C2 UA95099 C2 UA 95099C2
Authority
UA
Ukraine
Prior art keywords
iron
deferiprone
friedreich ataxia
ataxia resulting
treat friedreich
Prior art date
Application number
UAA200810608A
Other languages
English (en)
Ukrainian (uk)
Inventor
Арнольд Мунних
Майкл Спино
Иоав Кабанчик
Original Assignee
Арнольд Мунних
Майкл Спино
Иоав Кабанчик
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арнольд Мунних, Майкл Спино, Иоав Кабанчик filed Critical Арнольд Мунних
Publication of UA95099C2 publication Critical patent/UA95099C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение касается применения деферипрона или его физиологически приемлемой соли при лечении железо-индуцированного повреждения митохондрий, которое является следствием атаксии Фридрейха, при отсутствии общей перегрузки железа у пациента путем ежедневного введения до 30 мг/кг деферипрона.
UAA200810608A 2006-02-22 2007-02-21 Применение деферипрона при лечении железо-индуцированного повреждения митохондрий, который является следствием атаксии фридрейха UA95099C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77532006P 2006-02-22 2006-02-22

Publications (1)

Publication Number Publication Date
UA95099C2 true UA95099C2 (ru) 2011-07-11

Family

ID=38436879

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810608A UA95099C2 (ru) 2006-02-22 2007-02-21 Применение деферипрона при лечении железо-индуцированного повреждения митохондрий, который является следствием атаксии фридрейха

Country Status (24)

Country Link
US (3) US20090023784A1 (ru)
EP (1) EP1991225B1 (ru)
JP (1) JP5730466B2 (ru)
KR (1) KR20080104329A (ru)
CN (1) CN101420954A (ru)
AU (1) AU2007219009B2 (ru)
BR (1) BRPI0708211A2 (ru)
CA (1) CA2642778A1 (ru)
DK (1) DK1991225T3 (ru)
ES (1) ES2441065T3 (ru)
IL (1) IL193598A (ru)
MA (1) MA30266B1 (ru)
MX (1) MX2008010824A (ru)
MY (1) MY151412A (ru)
NZ (1) NZ570730A (ru)
PL (1) PL1991225T3 (ru)
PT (1) PT1991225E (ru)
RS (1) RS53225B (ru)
RU (1) RU2008137604A (ru)
SG (1) SG170020A1 (ru)
SI (1) SI1991225T1 (ru)
TN (1) TNSN08338A1 (ru)
UA (1) UA95099C2 (ru)
WO (1) WO2007095728A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY151412A (en) * 2006-02-22 2014-05-30 Munnich Arnold The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
CA2681545C (en) 2007-03-28 2013-10-01 Apotex Technologies Inc. Fluorinated derivatives of deferiprone
PL2268282T3 (pl) 2008-04-25 2015-04-30 Apotex Tech Inc Płynny preparat deferypronu o przyjemnym smaku
NZ594728A (en) 2009-01-26 2013-03-28 Univ Pennsylvania Use of deferiprone for treatment and prevention of iron-related eye disorders
ME01911B (me) 2009-07-03 2014-12-20 Apotex Tech Inc Fluorisani derivati 3-hidroksipiridin-4-ona
JP2012533601A (ja) 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
HRP20140570T1 (hr) 2010-08-30 2014-07-18 Roberto Testi Pripravci i postupci za tretiranje friedreichove ataksije pomoä†u interferon game
CN102861017A (zh) * 2011-07-08 2013-01-09 辽宁省计划生育科学研究院 一种化合物在防治老年痴呆的应用
WO2013139931A1 (en) * 2012-03-21 2013-09-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Composition for use in the treatment of neurodegenerative diseases with parkinsonian syndromes
US10442779B2 (en) 2014-09-22 2019-10-15 Fratagene Therapeutics S.R.L. Compositions and methods for treating Friedreich's ataxia
US10426775B2 (en) 2017-09-11 2019-10-01 Fratagene Therapeutics Srl Methods for treating Friedreich's ataxia with etravirine
DK3684344T3 (da) 2017-10-25 2025-08-04 Chiesi Farm Spa Deferipron-tabletter med forsinket frigivelse og fremgangsmåder til anvendelse deraf
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
EP4734990A1 (en) * 2023-06-28 2026-05-06 The United States of America, as Represented By the Secretary, Department of Health and Human Services Uses of iron chelators for treating stuttering

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624807A (en) * 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6133322A (en) * 1998-10-29 2000-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6933104B1 (en) * 1999-04-23 2005-08-23 Shiva Biomedical, Llc Diagnosis and treatment of human kidney diseases
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
US20040101521A1 (en) * 2002-07-12 2004-05-27 The Buck Institute For Research On Aging Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD OF TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF ACUTE INCREASES IN HYPERGLYCEMIA AND / OR ACUTE INCREASES OF FREE FATTY ACID FLOWS
US7728038B2 (en) * 2004-08-04 2010-06-01 University Of Utah Research Foundation Methods for chelation therapy
US20070197469A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V Fluoroquinolone carboxylic acid salt compositions
MY151412A (en) * 2006-02-22 2014-05-30 Munnich Arnold The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron

Also Published As

Publication number Publication date
BRPI0708211A2 (pt) 2011-05-17
MX2008010824A (es) 2009-06-08
MY151412A (en) 2014-05-30
IL193598A (en) 2012-08-30
AU2007219009A1 (en) 2007-08-30
KR20080104329A (ko) 2008-12-02
NZ570730A (en) 2013-05-31
DK1991225T3 (da) 2013-12-16
ES2441065T3 (es) 2014-01-31
US20130190365A1 (en) 2013-07-25
RU2008137604A (ru) 2010-03-27
CA2642778A1 (en) 2007-08-30
JP5730466B2 (ja) 2015-06-10
RS53225B (sr) 2014-08-29
PT1991225E (pt) 2014-02-13
CN101420954A (zh) 2009-04-29
WO2007095728A1 (en) 2007-08-30
IL193598A0 (en) 2009-08-03
EP1991225A1 (en) 2008-11-19
SG170020A1 (en) 2011-04-29
US20090023784A1 (en) 2009-01-22
EP1991225A4 (en) 2009-07-29
MA30266B1 (fr) 2009-03-02
JP2009527506A (ja) 2009-07-30
EP1991225B1 (en) 2013-11-06
TNSN08338A1 (en) 2009-12-29
US20070197649A1 (en) 2007-08-23
AU2007219009B2 (en) 2012-12-20
PL1991225T3 (pl) 2014-04-30
SI1991225T1 (sl) 2014-02-28

Similar Documents

Publication Publication Date Title
TNSN08338A1 (en) The use of deferiprone and methods to treat and/or prevent friedreich ataxia resulting from intracellular mishandling of iron
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MY163516A (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX365986B (es) Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal.
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
MX339614B (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
ME02841B (me) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
WO2011140232A3 (en) Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
WO2011017054A3 (en) Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
EA201291167A1 (ru) Замещенные гетероциклилбензилпиразолы и их применение
BR112012002246A2 (pt) composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
PH12015500012B1 (en) Benzodioxole derivative and preparation method and use thereof
MX2017011807A (es) Tratamiento de pacientes con diabetes mellitus tipo 2.
EA201391076A1 (ru) Комбинации
TN2011000678A1 (en) Fluorinated derivatives of 3-hydroxypyridin-4-ones
EA201270527A1 (ru) Комбинация
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease